NCT03913559 2026-02-12
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 2 Terminated
Clinical Trials
10 trialsNCT04846348 2024-04-25
Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis
Mayo Clinic
Phase 2 Terminated
NCT04840615 2024-02-02
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02999633 2022-03-21
ISLAY
Sanofi
Phase 2 Terminated
NCT01455389 2022-03-02
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
Genprex, Inc.
Phase 1/2 Terminated
NCT02606994 2019-02-06
TPvsM
Oral Defense, LLC
Phase 2 Terminated
NCT00482053 2018-05-14
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Stanford University
Phase 2 Terminated
NCT00226941 2017-12-08
A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
Stanford University
Phase 1/2 Terminated
NCT00429702 2014-07-25
Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy
University of South Florida
Phase 2 Terminated
NCT00887640 2014-02-26
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Duke University
Phase 2 Terminated